<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04281758</url>
  </required_header>
  <id_info>
    <org_study_id>PEP-1913</org_study_id>
    <nct_id>NCT04281758</nct_id>
  </id_info>
  <brief_title>Comparison of Plasma Caffeine Concentration After Oral Consumption of Caffeinated Beverages With Varied Bioactive Compounds in Healthy Volunteers</brief_title>
  <official_title>Comparison of Plasma Caffeine Concentration After Oral Consumption of Caffeinated Beverages With Varied Bioactive Compounds in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PepsiCo Global R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PepsiCo Global R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, double blind, randomized, controlled, cross-over trial.&#xD;
&#xD;
      The primary outcome is to quantify the incremental area-under-the-concentration-curve (iAUC)&#xD;
      for plasma caffeine after oral consumption of caffeinated beverages with various bioactive&#xD;
      compounds vs. caffeine alone, in 16 healthy volunteers&#xD;
&#xD;
      Secondary outcomes are caffeine concentration at each time point from pre-dose baseline to&#xD;
      3.5 hrs post-dose, peak caffeine concentration (Cmax), time to maximum caffeine concentration&#xD;
      (Tmax) and return to baseline concentration (TBR) for plasma caffeine&#xD;
&#xD;
      Other outcomes are ratings of physiological symptoms and mood, assessed using visual analog&#xD;
      scales (VAS).&#xD;
&#xD;
      Polyphenol food frequency questionnaire data at screening will be collected as a possible&#xD;
      co-variate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2020</start_date>
  <completion_date type="Actual">October 13, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Beverage types are as similar as possible in terms of taste, aroma and color.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incremental area-under-the-concentration-curve (iAUC)</measure>
    <time_frame>At each of 4 testing days, -30 and 0 min pre-dose, and 15, 30, 45, 60, 90, 120, 150, 180 and 210 minutes post-dose</time_frame>
    <description>Plasma caffeine level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Caffeine concentration</measure>
    <time_frame>At each of 4 testing days, -30 and 0 min pre-dose, and 15, 30, 45, 60, 90, 120, 150, 180 and 210 minutes post-dose</time_frame>
    <description>Plasma caffeine level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak caffeine concentration (Cmax)</measure>
    <time_frame>At each of 4 testing days, -30 and 0 min pre-dose, and 15, 30, 45, 60, 90, 120, 150, 180 and 210 minutes post-dose</time_frame>
    <description>Plasma caffeine level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration (Tmax)</measure>
    <time_frame>At each of 4 testing days, -30 and 0 min pre-dose, and 15, 30, 45, 60, 90, 120, 150, 180 and 210 minutes post-dose</time_frame>
    <description>Plasma caffeine level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to baseline concentration (TBR)</measure>
    <time_frame>At each of 4 testing days, -30 and 0 min pre-dose, and 15, 30, 45, 60, 90, 120, 150, 180 and 210 minutes post-dose</time_frame>
    <description>Plasma caffeine level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiological Symptoms</measure>
    <time_frame>At each of 4 testing days pre-dose, and 60 min, 120 min, and 210 min post-dose</time_frame>
    <description>VAS scale, 9 terms, each rated on a 100 mm line from &quot;Not at all&quot; to &quot;Extremely'. Example, not at all irritable is better than extremely irritable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bond-Lader Mood</measure>
    <time_frame>At each of 4 testing days pre-dose, and 60 min, 120 min, and 210 min post-dose</time_frame>
    <description>VAS scale,16 terms, each rated on a 100 mm line. Example, relaxed is better than tense.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Plasma Caffeine Concentration</condition>
  <arm_group>
    <arm_group_label>Caffeine beverage (control)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Flavored still beverage with caffeine 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caffeine beverage plus bioactive 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flavored still beverage with caffeine 100 mg + quercetin 250 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caffeine beverage plus bioactive 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flavored still beverage with caffeine 100 mg + curcumin 80 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caffeine beverage plus bioactive 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flavored still beverage with caffeine 100 mg + methylliberine 75 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Beverage</intervention_name>
    <description>16 oz (473.2 ml)</description>
    <arm_group_label>Caffeine beverage (control)</arm_group_label>
    <arm_group_label>Caffeine beverage plus bioactive 1</arm_group_label>
    <arm_group_label>Caffeine beverage plus bioactive 2</arm_group_label>
    <arm_group_label>Caffeine beverage plus bioactive 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult male volunteers aged 18 to 55 years.&#xD;
&#xD;
          2. Have a BMI of 18 to 29 kg/m2 (inclusive)&#xD;
&#xD;
          3. Able to comprehend and willing to sign an Informed Consent Form (ICF).&#xD;
&#xD;
          4. Willing to avoid caffeine for ≥48 hrs prior to visits&#xD;
&#xD;
          5. Willing to avoid alcohol for ≥24 hrs prior to visits&#xD;
&#xD;
          6. Willing to fast 10 hrs prior to visits&#xD;
&#xD;
          7. Willing to stick to their usual dietary patterns&#xD;
&#xD;
          8. Willing to stick to their usual physical activity level throughout the study&#xD;
&#xD;
          9. No participation in any clinical trial within the past 30 days or any PEP protocol&#xD;
             within the past 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Reported history or clinical manifestations of significant metabolic (including type 1&#xD;
             or type 2 diabetes mellitus), hepatic, renal, hematological, pulmonary,&#xD;
             cardiovascular, gastrointestinal, urological, neurological, or psychiatric disorders.&#xD;
&#xD;
          2. Current or recent history (&lt;30 days prior to Screening) of a clinically significant&#xD;
             bacterial, fungal, or mycobacterial infection&#xD;
&#xD;
          3. Current clinically significant viral infection&#xD;
&#xD;
          4. History of malignancy, with the exception of cured basal cell or squamous cell&#xD;
             carcinoma of the skin&#xD;
&#xD;
          5. Resting heart rate less than 45 bpm or greater than 100 bpm.&#xD;
&#xD;
          6. History of unstable ischemic heart disease or uncontrolled hypertension (blood&#xD;
             pressure greater than or equal to 150/90 mm Hg)&#xD;
&#xD;
          7. History of stomach or intestinal surgery, except that appendectomy and/or&#xD;
             cholecystectomy will be allowed.&#xD;
&#xD;
          8. Presence of a malabsorption syndrome possibly affecting drug/Product absorption (e.g.,&#xD;
             Crohn's disease or chronic pancreatitis).&#xD;
&#xD;
          9. Extreme dietary habits, including but not limited to vegetarian diets and intentional&#xD;
             consumption of a high fiber diet, gluten-free, low-carb, vegan, ketogenic.&#xD;
&#xD;
         10. History of alcoholism or drug addiction within 1 year prior to Screening, or current&#xD;
             alcohol or drug use that, in the opinion of the investigator, will interfere with the&#xD;
             subject's ability to comply with the dosing schedule and study evaluations.&#xD;
&#xD;
         11. Use of any tobacco-containing or nicotine-containing products (including cigarette,&#xD;
             pipe, cigar, chewing tobacco, nicotine patch, or nicotine gum and vaping products)&#xD;
             within 2 months prior to study entry.&#xD;
&#xD;
         12. Use of any prescription or nonprescription drugs (including vitamins, minerals, and&#xD;
             phytotherapeutic, herbal, or plant-derived preparations) is prohibited within 7 days&#xD;
             prior to the dose of study product, unless deemed acceptable by the Investigator.&#xD;
&#xD;
         13. Use of alcohol-containing within 24 hours prior to study entry.&#xD;
&#xD;
         14. Use of caffeine containing products 48 hours prior to each dose of study product and&#xD;
             during each dosing day.&#xD;
&#xD;
         15. Donation of blood in excess of 500 ml within 4 weeks prior to study entry or of plasma&#xD;
             within 2 weeks prior to Screening.&#xD;
&#xD;
         16. Receipt of blood products within 3 months prior to study entry.&#xD;
&#xD;
         17. Subjects who, in the opinion of the investigator, are unable or unlikely to comply&#xD;
             with the dosing schedule and study evaluations&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Trisha R Shamp, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prism Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prism Clinical Research</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 19, 2020</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>caffeine</keyword>
  <keyword>botanicals</keyword>
  <keyword>beverage</keyword>
  <keyword>mood</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

